Home World News FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma World News FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma By Ogkologos - October 19, 2026 313 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results of the RASolute 302 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR 5th Grader Follows His Gut By Calling 911 On School Bus... January 9, 2020 Los obstáculos en la atención para las personas LGBTQ con cáncer:... January 21, 2021 FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple... September 15, 2023 癌症可以在家族成员中被遗传吗？ October 13, 2020 Load more HOT NEWS Study Shows Music Eases Pain and Other Symptoms for Patients Undergoing... How radiotherapy became a lifesaver – from X-rays to the proton... High Frequency of Germline ATM Variants in CLL Your Microbiome and Cancer: What to Know
